These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21163809)

  • 1. Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol.
    Dósa E; Guillaume DJ; Haluska M; Lacy CA; Hamilton BE; Njus JM; Rooney WD; Kraemer DF; Muldoon LL; Neuwelt EA
    Neuro Oncol; 2011 Feb; 13(2):251-60. PubMed ID: 21163809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
    Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
    Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
    Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors.
    Thompson EM; Guillaume DJ; Dósa E; Li X; Nazemi KJ; Gahramanov S; Hamilton BE; Neuwelt EA
    J Neurooncol; 2012 Aug; 109(1):105-14. PubMed ID: 22528798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative comparison of delayed ferumoxytol T
    Horváth A; Varallyay CG; Schwartz D; Toth GB; Netto JP; Barajas R; Várallyay P; Szidonya L; Firkins J; Youngers E; Fu R; Ambady P; Bogner P; Neuwelt EA
    Magn Reson Med; 2018 Jul; 80(1):224-230. PubMed ID: 29205477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.
    Varallyay CG; Nesbit E; Horvath A; Varallyay P; Fu R; Gahramanov S; Muldoon LL; Li X; Rooney WD; Neuwelt EA
    J Magn Reson Imaging; 2018 Aug; 48(2):441-448. PubMed ID: 29314418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
    Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
    AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
    Gahramanov S; Muldoon LL; Li X; Neuwelt EA
    Radiology; 2011 Dec; 261(3):796-804. PubMed ID: 21940504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI using ferumoxytol improves the visualization of central nervous system vascular malformations.
    Dósa E; Tuladhar S; Muldoon LL; Hamilton BE; Rooney WD; Neuwelt EA
    Stroke; 2011 Jun; 42(6):1581-8. PubMed ID: 21493906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle.
    Varallyay CG; Nesbit E; Fu R; Gahramanov S; Moloney B; Earl E; Muldoon LL; Li X; Rooney WD; Neuwelt EA
    J Cereb Blood Flow Metab; 2013 May; 33(5):780-6. PubMed ID: 23486297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
    Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
    Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
    Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
    Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).
    Maravilla KR; Smith MP; Vymazal J; Goyal M; Herman M; Baima JJ; Babbel R; Vaneckova M; Žižka J; Colosimo C; Urbańczyk-Zawadzka M; Mechl M; Bag AK; Bastianello S; Bueltmann E; Hirai T; Frattini T; Kirchin MA; Pirovano G
    AJNR Am J Neuroradiol; 2015 Jan; 36(1):14-23. PubMed ID: 25300984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.
    Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ
    Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose gadoteridol in MR imaging of intracranial neoplasms.
    Runge VM; Kirsch JE; Burke VJ; Price AC; Nelson KL; Thomas GS; Dean BL; Lee C
    J Magn Reson Imaging; 1992; 2(1):9-18. PubMed ID: 1623287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.
    Siedek F; Muehe AM; Theruvath AJ; Avedian R; Pribnow A; Spunt SL; Liang T; Farrell C; Daldrup-Link HE
    Eur Radiol; 2020 Mar; 30(3):1790-1803. PubMed ID: 31844962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.